ARO-ATXN2
/ Arrowhead Pharmaceuticals, Sarepta Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 30, 2026
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
(clinicaltrials.gov)
- P1 | N=39 | Active, not recruiting | Sponsor: Arrowhead Pharmaceuticals | Recruiting ➔ Active, not recruiting
Enrollment closed • Ataxia • Movement Disorders
August 21, 2025
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Trial completion date: Sep 2026 ➔ Dec 2026 | Trial primary completion date: Sep 2026 ➔ Dec 2026
Trial completion date • Trial primary completion date • Ataxia • Movement Disorders
1 to 2
Of
2
Go to page
1